Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?

Last week, Hologic (HOLX) earned two key regulatory approvals. The company’s Affirm Contrast Biopsy software has earned the CE Mark, having previously been cleared by the FDA in October 2020. Meanwhile, the Aptima SARS-CoV-2 assay, initially granted Emergency Use Authorization status in May 2020, has now achieved the FDA’s 510k clearance.These advancements come after Hologic’s fiscal 2025 first-quarter report, released earlier this month, which reflected strengths and challenges within the divisions and fro ...